ReviewEndocrine pathology2012
Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.
Review in Endocrine pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Pooled it
- Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas.Annals of medicine · 2025Article
- Presurgical Succinate MetAstatic Risk Tool (P-SMART) in Paragangliomas.Endocrine pathology · 2025Article
- Heart failure induced by a tumor in a young adult woman: A case report of dilated cardiomyopathy triggered by paraganglioma.Radiology case reports · 2025Article
- The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease.Endocrine pathology · 2024Review
- Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma.Diagnostics (Basel, Switzerland) · 2024Article
- Hybrid imaging of neuroendocrine tumors in the heart: Union is strength.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.Endocrine pathology · 2022Review
- Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.Journal of endocrinological investigation · 2022Article
- Malignant prediction in paragangliomas: analysis for clinical risk factors.Langenbeck's archives of surgery · 2021Article
- Young woman diagnosed with paraganglioma in primary care.BMJ case reports · 2021Article
- Diagnosis and treatment of a rare tumor-bladder paraganglioma.Molecular and clinical oncology · 2020Article
- Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years.Endocrine pathology · 2020Article
- Pheochromocytoma and Paraganglioma: A Review of Diagnosis, Management and Treatment of Rare Causes of Hypertension.Cureus · 2020Review
- Malignant Pheochromocytomas/Paragangliomas and Ectopic Hormonal Secretion: A Case Series and Review of the Literature.Cancers · 2019Review
- Diagnosis of functional paraganglioma by ultrasonographer squeezing the retroperitoneal tumor and measuring the change of blood pressure: A case presentation.Quantitative imaging in medicine and surgery · 2019Article
- Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center.Endocrine · 2018Article
- The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations.Journal of clinical medicine · 2018Review
- Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine.Journal of clinical medicine · 2018Review
- Heart combined with adrenal multiple pheochromocytomas.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The laboratory workup of patients with pheochromocytoma and extra-adrenal paraganglioma (PPGLs) has traditionally focused on biochemical measurements of tumor secretory products or their metabolites, with ultimate diagnosis resting on routine histopathology and immunohistochemistry. While such testing remains important, the needs to distinguish potentially metastatic from benign tumors and to identify tumors with a hereditary basis have stimulated searches for additional means to stratify patients according to risk of metastasis or presence of a particular mutation. Biomarkers based on traditional biochemical tests, such as profiles of catecholamine metabolites and granin-derived peptides, provide utility for both purposes, while novel biomarkers are being identified by proteomic and transcriptomic studies, the latter including microRNA expression profiling. Histopathological scoring methods for predicting metastatic potential, such as the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS), are limited by poor interobserver concordance, discrepant results between studies and incomplete knowledge of how scores relate to genotype. Immunohistochemical staining for succinate dehydrogenase (SDH) subunit B to triage patients for genetic testing of SDH subunit genes illustrates the growing importance of pathology as an adjunct to genetic testing for disease stratification. Although considerable effort has been expended on microarray-based platforms to identify biomarkers of malignancy, as yet, none of those proposed have been demonstrated to reliably discriminate malignant from benign disease any better than the PASS. Because of the heterogeneity of PPGLs and variable time between first appearance of tumors and identification of metastases, any prospective study to establish prognostic efficacy requires large numbers of patients and extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.